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with headache symptoms (16.97 o 0.54 vs. 5.38 o 0.39, p  0.0001). CM also missed 
more days due to illnesses other than headache than EM participants (13.66 o 1.98 
vs. 9.33 o 1.42, p  0.01). CM and EM reported working at about half of their full 
effectiveness with headache symptoms (p  0.05). CM reported experiencing more 
impairment on work ability or activity than EM (CM  31.1%, EM  24.4%), or 
requiring more bed rest (CM  33.5%, EM  26.2%) when experiencing severe 
headaches. CONCLUSIONS: Migraine adversely affected presenteeism and increased 
absenteeism of migraine sufferers, particularly among those with CM, who missed 
more days and worked more days with headache than EM.
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COSTS OF ILLNESS IN PARKINSON’S DISEASE IN SIX EUROPEAN 
COUNTRIES
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OBJECTIVES: To evaluate the direct and indirect costs of Parkinson´s Disease (PD) 
in a survey of ﬁve European countries and Russia. So far, cost-of-illness (COI) studies 
on PD have been conducted in some European countries only, none in Austria, Czech 
Republic, Portugal and Russia. The prevalence of PD in Europe varies between 115 
and 221 per 100,000, due to aging of population the number of persons affected is 
expected to double within the next 25 years. METHODS: Between 2003—2005 about 
100 patients of PD were recruited per study center. Clinical status (Hoehn & Yahr 
stage, Uniﬁed Parkinson’s Disease Rating Scale) was evaluated. Economic data were 
collected over a 6 months period using the “bottom-up” approach. Indirect costs were 
calculated by the human capital approach. Informal care was monetary valued. 
RESULTS: The total mean costs per patient ranged from a2620 to a9812 for the 6-
months observation period. Direct costs made about 60% to 70%, indirect costs made 
30% to 40% of total costs. Forty-seven percent to 92% of direct costs were on the 
account of the national health insurance systems. Patients’ co-payments constituted 
up to 14% of direct costs. Informal care generally was the prevalent form of care for 
PD patients. In half of the participating countries it was the major source of expendi-
ture. CONCLUSIONS: This is the ﬁrst observational study on the burden of PD across 
European countries and Russia. Costs of PD across Europe vary considerably. Reasons 
are multiple; differences in prices, health systems and traditions are some. PD repre-
sents a major burden on the individual, family, health services and society in Europe, 
especially in Eastern European countries. A major cost factor is the cost for care, which 
has enormous importance due to demographic development and extension of life 
expectancy.
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THE POTENTIAL ECONOMIC IMPACT OF GENERIC SUBSTITUTION OF 
TOPIRAMATE ON HEALTH CARE COSTS IN THE G4 EUROPEAN 
COUNTRIES
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OBJECTIVES: To examine the economic impact of generic substitution of the anti-
epileptic drug (AED) Topiramate in Canada; and convert observed Canadian costs 
into the settings of France, Germany, Italy and the UK (UK). METHODS: Retrospec-
tive health claims from Québec’s provincial health plan (RAMQ) between January 
2006 and September 2008, and IMS Health data on European AED sales between 
1998 and 2008 were used. Patients with epilepsy (ICD-9: 345, 780.3, 780.39) and q2 
topiramate dispensings were selected. Patient-level health care utilization costs in 
Canada were calculated during mutually-exclusive periods of brand versus generic use 
of topiramate. Annualized Canadian health care costs were projected in each country 
(a2007/person-year) using Canadian rates, European prices and service-use ratios. 
Using market-level sales, topiramate utilization were forecasted for 12 months follow-
ing expected generic entry (September 2009-September 2010) using autoregressive and 
panel-data regression models. The impact of generic entry was projected for each 
country, stratiﬁed into its effect on market size, topiramate costs, and other health 
care costs. RESULTS: A total of 1164 patients (mean age: 39.8 years, 61.7% female) 
were observed for 2.6 years on average. Projected per-patient health care costs in G4 
European countries, excluding Topiramate, would be signiﬁcantly higher during 
generic-use periods (adjusted cost differences per person-year: a706 to a815, p  0.001 
for all comparisons) compared to brand-use periods. Assuming mandatory generic 
substitution for all patients, predicted system-wide increases in total adjusted health 
care costs would range from 3.5% (UK) to 24.4% (France) one year after generic 
entry. Increases in non-Topiramate health care costs (13.7% to 18.1%) would more 
than offset savings in incremental Topiramate brand costs (6.3% to 13.8%) in 
France, Italy, and the UK. CONCLUSIONS: The generic entry of Topiramate in 
Europe is projected to be associated with higher health care costs, representing a 
trade-off between reduced generic drug expenditures and increased health care 
costs.
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OBJECTIVES: investigated the impact of generic substitution of the branded antiepi-
leptic drug (AED) Topiramate (Topamax®) on medical service utilization and costs 
for patients with epilepsy in Germany. METHODS: Retrospective health claims from 
Québec’s provincial health plan (RAMQ) between January 2006 and September 2008 
were analyzed. Patients with epilepsy (ICD-9: 345, 780.3 or 780.39) and q2 topira-
mate (Topamax®) dispensings were selected. Patient-level health care utilization and 
costs in Canada were calculated during mutually-exclusive periods of brand versus 
generic use of topiramate. Annualized Canadian health care costs were converted into 
a German setting (a2007/person-year) by applying purchasing power parities, service-
use ratios and exchange rates. Using market-level sales, branded and generic topira-
mate utilization were forecasted for 12 months following expected generic entry 
(September 2009-September 2010) using autoregressive and panel-data regression 
models. Non-parametric bootstrap procedure was used to determine statistical signiﬁ-
cance for the cost measures. Budgetary consequences for sick funds, individual and 
private payers were assessed. RESULTS: After adjusting for covariates, periods of 
generic topiramate use were associated with signiﬁcant increases in pharmacy dispens-
ings (other AEDs: 6%, non-AEDs: 31%, p  0.001), a 17% increase in hospitaliza-
tions (p  0.015), and 21% longer lengths of hospital stays (p  0.001). Converted 
per-patient health care costs excluding topiramate were estimated to be signiﬁcantly 
higher for generic relative to brand periods in Germany (adjusted cost difference per 
person-year [95% CI]: a710 [a149–a1283]; p  0.001). Assuming mandatory generic 
substitution for all patients, predicted system-wide increase in total adjusted health 
care costs would be 23.2% one year after generic entry. This impact would be evenly 
distributed among payers. CONCLUSIONS: Generic entry of topiramate in Germany 
would represent a trade-off between reduced generic drug expenditures and increased 
health care costs due to higher AED and non-AED spending, as well as increased 
hospitalizations and outpatient visits. Increased total cost is expected to outweigh the 
beneﬁt of reduced drug costs.
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OBJECTIVES: In addition to medical treatment, deep brain stimulation (DBS) has 
become an alternative therapeutical option in advanced Parkinson’s disease, especially 
for motor complications such as dyskinesias or motor ﬂuctuations. High initial costs 
of surgery and subsequent time-consuming maintenance procedures may be traded off 
by long-term gains in quality of life (HrQoL) compared to conventional medication 
treatment. This leads to the question whether DBS is cost effective compared to best 
medical treatment. METHODS: We present a lifetime Markov model for Parkinson’s 
disease, comparing deep brain stimulation vs. best medical treatment and estimating 
the impact on health-related quality of life. HrQoL was measured by the EQ-5D and 
cost from the societal perspective of Germany. Both were discounted with 3% p.a.. 
Data on DBS efﬁcacy and adverse events were taken from clinical studies and pub-
lished reports or meta-analyses. Key assumptions on the surgery procedure and its 
durability, its impact on cost and HrQoL, mortality, prevalence of motor complica-
tions as well as stage transition probabilities and the discount rate were investigated 
by one- and two-way sensitivity analyses. RESULTS: The incremental cost effective-
ness ratio (ICER) for DBS was a42,183 per QALY gained. Incremental DBS costs were 
due to cost for surgery and subsequent battery change. HrQoL was improved and 
motor complications were reduced. The following variables had most impact in sen-
sitivity analyses: utility improvement under DBS, drug and surgery cost, progression 
rates, and discount rate leading to varying ICERs between 20,064 and a58,147/QALY 
(the latter due to extreme and unlikely parameter combinations). CONCLUSIONS: 
Based on our decision analysis using current guidelines, DBS is likely to be cost-
 effective compared with other well-accepted health care technologies. We suggest to 
adopt DBS for patients with high drug cost or severe motor complications.
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PREVENTION OF CSF LEAKS IN FRENCH HOSPITALS
Castanier JC1, Maunoury F2, Hédoux S3, Auffrand M3
1Independent Consultant in Health Economics, Lyon, France, 2STATESIA, Le Mans, France, 
3FRAVIMED, Lyon, France
OBJECTIVES: The objective was to demonstrate the cost-effectiveness of a new 
absorbable hydrogel used in craniotomies compared to the option “do nothing” in 
France. METHODS: A Markov model was fed with clinical data from Grotenhuis 
and al. (Surg. Neurol. 2005;64:490–3) and with cost data from the French cost data-
base (2006 data based on DRG (GHM) 01C04V craniotomy without complication 
and 01C04W craniotomy with complication). The model was run with three stages 
(T0: date of surgery; T1: 1-month follow-up; T2: 3-month follow-up) and three states 
Paris Abstracts A369
(no CSF leak; CSF leak; death). The effectiveness outcome measure was a utility index 
given to each state based on the hypothesis that utility was 1 for “no CSF leak”; 0.5 
for “CSF leak” and 0 for “death”. RESULTS: When hydrogel was used, the probabili-
ties were for no CSF leak 1.000 at T0; 0.936 at T1 and 0.876 at T2; for CSF leak 
0.000 at T0; 0.043 at T1 and 0.082 at T2; and for death 0.000 at T0; 0.021 at T1 
and 0.042 at T2. When no hydrogel was used, the probabilities were for no CSF leak 
0.060 at T0; 0.876 at T1; 0.767 at T2; for CSF leak 0.940 at T0; 0.103 at T1 and 
0.191 at T2; and for death 0.000 at T0; 0.021 at T1 and 0.042 at T2. The cost-
 effectiveness ratio was a4,720.20 at T0; a5,174.29 at T1 and a5,645.06 at T2 
when hydrogel was used and it was a27,693.48 at T0; a14,251.71 at T1 and 
a12,638.00 at T2 when hydrogel was not used. The ICER, which represents 
the additional cost necessary to gain one additional utility unit, was a9857.12. 
 CONCLUSIONS: The strategy with hydrogel was more cost-effective than the 
strategy without hydrogel.
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OBJECTIVES: Sugammadex (SGX) is a modiﬁed G-cyclodextrin that has been recently 
marketed in Spain for the reversal of neuromuscular block induced by rocuronium 
(ROC) and vecuronium. The objective of this study was to evaluate the cost-
 effectiveness of sugammadex in the management of patients with unanticipated 
 difﬁcult intubation and patients needing rapid sequence intubation from the Spanish 
National Health System perspective. METHODS: Two decision-analytic models were 
developed to assess the average per patient treatment costs (a2009), life-years gained, 
and incremental cost per life-year gained of ROC  SGX vs. succinylcholine in patients 
needing rapid sequence intubation and ROC SGX vs. all other neuromuscular block-
ing agents in the management of the unanticipated difﬁcult intubation patients. The 
models simulate the probability of not being able to intubate, the probability of 
experiencing an adverse effect, and the direct costs produced by each treatment alter-
native. Clinical data was obtained from the SmPC of each drug and form secondary 
sources. Costs were obtained for Soikos database. All data was validated by a focus 
group in order to adapt the model to the Spanish clinical practice. RESULTS: In the 
management of unanticipated difﬁcult intubation patients, ROCSGX is associated 
with higher life years gained and less costs than the intubation with atracurium or 
cisatracurium and with a mean cost per life year gained (LYG) of a11,077 vs. succi-
nylcholine based regimens. In the rapid sequence intubation model, ROCSGX is 
associated with mean expected costs of a58.11 and mean expected life years of 20.38, 
and succinylcholine with a57.89 and 20,37, meaning a cost per LYG of ROCSGX 
vs succinylcholine of a3106. CONCLUSIONS: Under the established assumptions, 
sugammadex would be a cost-effective alternative for the reversal of patients with 
unanticipated difﬁcult intubation or for the management of patients undergoing rapid 
sequence intubation.
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REVERSAL OF NEUROMUSCULAR BLOCKADE WITH SUGAMMADEX—
COST-EFFECTIVENESS ANALYSIS
Calado F1, Félix J2, Rabiais S1, Vilela H3
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OBJECTIVES: To assess the cost-effectiveness of sugammadex for reversal of neuro-
muscular blockade (NMB) in Portuguese hospitals, using a clinical decision model. 
METHODS: We compared sugammadex 2.0 mg/kg with neostigmine 50 Mg/kg plus 
atropine 0.375 mg. Clinical efﬁcacy and safety data were obtained from both pub-
lished literature and phase III randomized clinical trial supporting the need for routine 
reversal of rocuronium or vecuronium NMB. Clinical events considered were drug 
adverse reactions and post-operative residual curarization. Risk of death within hos-
pitalization, duration and cost of hospitalization were estimated from hospitalizations 
in Portuguese public hospitals during 2007, with at least one surgical procedure. Only 
direct costs were considered (drugs, medical visits, side effect treatments and monitor-
ing). Effectiveness was measured in life years (LY). Premature death accounted to LY 
as the loss of remaining lifespan. Monte Carlo simulations were used to assess second-
order uncertainty. RESULTS: NMB reversal with sugammadex was estimated to result 
in a per patient gain of 2.25 LY (95%CI [1.78; 2.74]) and a decrease of a1509 (95%CI 
[-6,148; 738]) on total cost when compared to the neostigmine-atropine alternative, 
being on average a dominant strategy. Probabilistic sensitivity analysis revealed 82.6% 
probability of sugammadex dominance and 100% of being cost-effective at a thresh-
old of a1000. CONCLUSIONS: Neuromuscular blockade reversal with sugammadex 
may be considered a cost-effective strategy in comparison to neostigmine-atropine.
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OBJECTIVES: We examined whether rasagiline, a once-daily irreversible monoamine 
oxidase type-B inhibitor indicated for treatment of early Parkinson’s disease, is a 
cost-effective ﬁrst-line treatment strategy when compared with ropinirole XL, prami-
pexole, generic ropinirole, and ﬁrst-line levodopa. METHODS: We developed a 5-year 
Markov model to examine the cost-effectiveness of initiating early treatment of PD 
with rasagiline from a United States payer perspective. Comparator strategies included 
initiating therapy with ropinirole XL, pramipexole, generic ropinirole, or levodopa. 
Rasagiline was followed by either a dopamine agonist (DA) or levodopa. DA was 
followed by levodopa. Patients on a DA or levodopa could develop dyskinesias. Health 
state transitions occurred every 6 months. Transition probabilities were from clinical 
trial data. Drug costs, medical costs and utility weights were from published sources. 
One-way and probabilistic sensitivity analyses were performed. Costs and outcomes 
were discounted at 3% per year. RESULTS: Over 5 years, ﬁrst-line treatment with 
rasagiline was cost saving and more effective when compared to branded DAs and 
levodopa. Rasagiline was cost-effective versus generic ropinirole at $1,838 per quality-
adjusted life-year (QALY): incremental costs $239 and incremental QALYs 0.13. 
After ﬁve years compared to a DA, 23% and 50% fewer patients who initiated treat-
ment with rasagiline were taking levodopa and experiencing dyskinesias respectively. 
Compared to ﬁrst-line levodopa, 52% and 69% fewer patients starting rasagiline were 
taking levodopa and experiencing dyskinesias respectively. CONCLUSIONS: Initiat-
ing early Parkinson’s disease therapy with rasagiline delayed treatment with levodopa, 
reduced dyskinesias, and appears to be cost-savings or cost-effective when compared 
to initiating therapy with other ﬁrst-line therapies.
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OBJECTIVES: The societal costs of caring for patients with Alzheimer’s disease 
(AD) are substantial. In light of increasing AD prevalence, there is a need for efﬁcient 
allocation of available resources and despite few therapeutic alternatives the cost-
effectiveness of treatment with cholinesterase inhibitors has been the issue of much 
debate. The objective of this study was to use recently collected data on costs and 
utilities at different stages of AD to estimate the cost-effectiveness of donepezil com-
pared to placebo in mild-to-moderate AD in Sweden. METHODS: A twelve state 
Markov-model was developed, incorporating cognitive function (mild/moderate/
severe), ADL-dependency (independent/dependent) and care setting (home/institution). 
Data on efﬁcacy and disease progression were based on a 1-year clinical trial in 
Northern Europe and costs and utilities were based on a recently conducted cost-of-
illness study in Sweden. The cohort was simulated over ﬁve years in 6-month cycles. 
Patients were assumed to receive treatment during one year, and after that disease 
progression rates were assumed to be identical in the donepezil and the placebo group. 
RESULTS: In base case scenario, the treatment cost of donepezil (11,023 SEK) was 
offset by lower other costs of care (17,618 SEK), resulting in an overall cost-saving 
of 6595 SEK per patient compared to placebo. Donepezil treatment also delayed pro-
gression into severe AD, ADL-dependence and institutionalization and led to a gain 
of 0.056 quality-adjusted life-years (QALY). Sensitivity analyses were carried to 
analyze the impact of extending the period under which treatment costs were incurred 
and by altering the baseline characteristics. Donepezil was cost-saving in most of these 
alternative scenarios and cost-effective in all of them. CONCLUSIONS: Using new 
data on costs and utilities in AD, donepezil treatment in mild-to-moderate AD is 
cost-saving compared to placebo. Treatment delays progression into severe AD, ADL-
dependence and institutionalization and thereby leads to QALY gains.
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HEALTH ECONOMIC EVALUATION OF LAMOTRIGINE VERSUS 
LEVETIRACETAME IN THE INITIAL MONOTHERAPY OF EPILEPSY 
(LALIMO-TRIAL)
Balzer-Geldsetzer M, Reese JP, Rosenow F, Strzelczyk A, Hamer HM, Dodel R
Philipps University, Marburg, Germany
OBJECTIVES: Health economic evaluation on the relative value of lamotrigine (LTG) 
and levetiracetame (LEV) in the initial monotherapy of epilepsy METHODS: Paral-
leling an open label, prospective, randomised, multicenter trial including 409 epilepsy 
patients, a health economic evaluation of 81 participants aged q18 years was con-
ducted. Data collection was done by the CRF of the clinical trial and in a series of 
three telephone interviews (baseline and two follow up calls, 3 and 6 months after 
baseline, respectively). The telephone interviews comprised sociodemographics, as well 
as instruments for the evaluation of health-related quality of life, depression and 
resource use). RESULTS: Eighty-one epilepsy patients were included in the economic 
evaluation. Thirty-eight (46.9%) patients were female: 21 (53.8%) in the LTG arm 
and 17 (40.5%) in the LEV arm. The mean duration of the disease was 2.0 o 3.9 
years (LTG) and 2.2 o 6.1 years (LEV). Over the survey period, there was no signiﬁcant 
difference concerning the number of ambulatory consultations (LTG 28 vs. LEV 26) 
or stationary hospital care (LTG 33 vs. LEV 38), though there was a trend for more 
